Open AccessReal-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma
Author(s) -
Hsu-Chih Chien,
Deborah Morreall,
Vikas Patil,
Kelli M Rasmussen,
Chunyang Li,
Christina Yong,
Zachary Burningham,
Anthony Masaquel,
M. Elizabeth Halloran,
Elisha De Long-Sieg,
Manfred Schulz,
Brian C. Sauer,
Ahmad Halwani
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-0522
Subject(s) - medicine , refractory (planetary science) , diffuse large b cell lymphoma , lymphoma , veterans affairs , overall survival , bone marrow transplant , oncology , cancer , salvage therapy , bone marrow , chemotherapy , bone marrow transplantation , physics , astrobiology
Aim: To describe practices and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Using Veteran Affairs Cancer Registry System and electronic health record data, we identified relapsed/refractory diffuse large B-cell lymphoma patients completing second-line treatment (2L) in 2000–2016. Treatments were classified as aggressive/nonaggressive. Analyses included descriptive statistics and the Kaplan–Meier estimation of progression-free survival and overall survival. Results: Two hundred and seventy patients received 2L. During median 9.7-month follow-up starting from 2L, 470 regimens were observed, averaging 2.7 regimens/patient: 219 aggressive, 251 nonaggressive. One hundred and twenty-one patients proceeded to third-line, 50 to fourth-line and 18 to fifth-line treatment. Median progression-free survival in 2L was 5.2 months. Median overall survival was 9.5 months. Forty-four patients (16.3%) proceeded to bone marrow transplant. Conclusion: More effective, less toxic treatments are needed and should be initiated earlier in treatment trajectory.